NZ601126A - Voltage-gated sodium channel blockers - Google Patents
Voltage-gated sodium channel blockersInfo
- Publication number
- NZ601126A NZ601126A NZ601126A NZ60112611A NZ601126A NZ 601126 A NZ601126 A NZ 601126A NZ 601126 A NZ601126 A NZ 601126A NZ 60112611 A NZ60112611 A NZ 60112611A NZ 601126 A NZ601126 A NZ 601126A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methyl
- formula
- disclosed
- compound
- phenyl
- Prior art date
Links
- 239000000664 voltage gated sodium channel blocking agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 206010006451 bronchitis Diseases 0.000 abstract 2
- -1 piperazine compound Chemical class 0.000 abstract 2
- GEXJFIOPGAASTP-UHFFFAOYSA-N $l^{1}-azanylethane Chemical compound CC[N] GEXJFIOPGAASTP-UHFFFAOYSA-N 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 208000018569 Respiratory Tract disease Diseases 0.000 abstract 1
- SGDNBFUALVARSN-FHQKDBNESA-N [O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.FC=1C=CC=C(Cl)C=1C[NH+](CC)CC(C=C1)=CC=C1C[NH+](CC1)CCN1C1=NC=CC=C1C(=O)OC(C)C.FC=1C=CC=C(Cl)C=1C[NH+](CC)CC(C=C1)=CC=C1C[NH+](CC1)CCN1C1=NC=CC=C1C(=O)OC(C)C Chemical compound [O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.FC=1C=CC=C(Cl)C=1C[NH+](CC)CC(C=C1)=CC=C1C[NH+](CC1)CCN1C1=NC=CC=C1C(=O)OC(C)C.FC=1C=CC=C(Cl)C=1C[NH+](CC)CC(C=C1)=CC=C1C[NH+](CC1)CCN1C1=NC=CC=C1C(=O)OC(C)C SGDNBFUALVARSN-FHQKDBNESA-N 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 208000013116 chronic cough Diseases 0.000 abstract 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-M nicotinate Chemical compound [O-]C(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-M 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29513810P | 2010-01-14 | 2010-01-14 | |
| US31700510P | 2010-03-24 | 2010-03-24 | |
| PCT/US2011/021114 WO2011088201A1 (en) | 2010-01-14 | 2011-01-13 | Voltage-gated sodium channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ601126A true NZ601126A (en) | 2014-10-31 |
Family
ID=44304640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ601126A NZ601126A (en) | 2010-01-14 | 2011-01-13 | Voltage-gated sodium channel blockers |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20130023541A1 (enExample) |
| EP (1) | EP2523665A4 (enExample) |
| JP (1) | JP2013517283A (enExample) |
| KR (1) | KR20120124064A (enExample) |
| CN (1) | CN102802627A (enExample) |
| AR (1) | AR079906A1 (enExample) |
| AU (1) | AU2011205302B2 (enExample) |
| BR (1) | BR112012017266A2 (enExample) |
| CA (1) | CA2787025A1 (enExample) |
| CL (1) | CL2012001971A1 (enExample) |
| CO (1) | CO6592051A2 (enExample) |
| CR (1) | CR20120402A (enExample) |
| EA (1) | EA201290644A1 (enExample) |
| IL (1) | IL220836A0 (enExample) |
| MA (1) | MA33987B1 (enExample) |
| MX (1) | MX2012008285A (enExample) |
| NZ (1) | NZ601126A (enExample) |
| PE (1) | PE20121518A1 (enExample) |
| PH (1) | PH12012501421A1 (enExample) |
| SG (1) | SG182400A1 (enExample) |
| TW (1) | TW201139406A (enExample) |
| UY (1) | UY33186A (enExample) |
| WO (1) | WO2011088201A1 (enExample) |
| ZA (1) | ZA201205126B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2963028B1 (en) | 2009-05-27 | 2018-08-01 | Atir Holding S.A. | Piperazine derivatives and their pharmaceutical use |
| KR101178181B1 (ko) * | 2010-09-17 | 2012-09-19 | 대한민국(농촌진흥청장) | 신규한 항생활성 화합물 및 그 화합물을 포함하는 항생 조성물 |
| WO2012049555A1 (en) | 2010-10-13 | 2012-04-19 | Lupin Limited | Spirocyclic compounds as voltage-gated sodium channel modulators |
| EA201490210A1 (ru) * | 2011-07-06 | 2014-05-30 | Глэксо Груп Лимитед | Блокаторы потенциалзависимых натриевых каналов |
| ES2586213T3 (es) * | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| MX2014005304A (es) * | 2011-10-31 | 2015-03-20 | Xenon Pharmaceuticals Inc | Biaril eter sulfonamidas y su uso como agentes terapeuticos. |
| US9012450B2 (en) | 2011-12-28 | 2015-04-21 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| PL2797416T3 (pl) | 2011-12-28 | 2017-12-29 | Global Blood Therapeutics, Inc. | Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek |
| CA2874621A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
| US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| ES2750640T3 (es) * | 2012-08-16 | 2020-03-26 | Scripps Research Inst | Ligandos opioides kappa novedosos |
| CN105263490B (zh) | 2013-03-14 | 2018-05-22 | 基因泰克公司 | 取代的三唑并吡啶及其使用方法 |
| ES2663798T3 (es) | 2013-03-14 | 2018-04-17 | Daiichi Sankyo Company, Limited | Fármaco para enfermedades respiratorias |
| JP6426694B2 (ja) | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| CA2898680A1 (en) | 2013-03-15 | 2014-09-18 | Genentech,Inc. | Substituted benzoxazoles and methods of use thereof |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EP2968299B1 (en) | 2013-03-15 | 2021-01-20 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| BR112015021982B1 (pt) | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
| PE20151907A1 (es) * | 2013-03-15 | 2016-01-20 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10005720B2 (en) | 2013-04-05 | 2018-06-26 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| JP6383418B2 (ja) | 2013-11-27 | 2018-08-29 | ジェネンテック， インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
| US9975876B2 (en) | 2013-12-09 | 2018-05-22 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists |
| JP6045487B2 (ja) * | 2013-12-25 | 2016-12-14 | シャープ株式会社 | 操作入力システム、電子機器、携帯端末、及び操作入力方法 |
| AP2016009261A0 (en) | 2014-02-07 | 2016-06-30 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| AU2015223049B2 (en) * | 2014-02-27 | 2019-03-21 | Merck Patent Gmbh | Heterocyclic compounds as NaV channel inhibitors and uses thereof |
| TW201623264A (zh) | 2014-03-29 | 2016-07-01 | 魯賓有限公司 | 作為電位閘控鈉通道調節劑之磺胺化合物 |
| CN106715418A (zh) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | 治疗化合物及其使用方法 |
| WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| MA42118A (fr) | 2015-05-22 | 2018-03-28 | Genentech Inc | Benzamides substitués et leurs méthodes d'utilisation |
| WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| TW201722938A (zh) | 2015-09-04 | 2017-07-01 | 魯賓有限公司 | 作為電位閘控鈉通道調節子之磺醯胺化合物 |
| JP6987746B2 (ja) | 2015-09-28 | 2022-01-05 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| US10899732B2 (en) | 2015-11-25 | 2021-01-26 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| PL3383392T3 (pl) | 2015-12-04 | 2025-11-17 | Global Blood Therapeutics, Inc. | Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu |
| JP2019505508A (ja) | 2016-02-03 | 2019-02-28 | シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． | 複素環置換ｎ−スルホニルベンズアミド誘導体、その製造方法および医薬における使用 |
| US10766858B2 (en) | 2016-03-30 | 2020-09-08 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| BR112019007763A2 (pt) | 2016-10-17 | 2019-07-02 | Genentech Inc | composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção |
| WO2018163077A1 (en) | 2017-03-08 | 2018-09-13 | Lupin Limited | Indanyl compounds as voltage gated sodium channel modulators |
| EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| WO2019191702A1 (en) | 2018-03-30 | 2019-10-03 | F. Hoffmann-La Roche Ag | Substituted hydro-pyrido-azines as sodium channel inhibitors |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
| CN109796402A (zh) * | 2018-12-28 | 2019-05-24 | 京博农化科技有限公司 | 一种烟嘧磺隆中间体2-氯-n，n-二甲基烟酰胺的制备方法 |
| KR102845511B1 (ko) * | 2019-02-08 | 2025-08-12 | 삼성디스플레이 주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| US12240855B2 (en) | 2019-03-06 | 2025-03-04 | Daiichi Sankyo Company, Limited | Pyrrolopyrazole derivative |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2325140T3 (es) * | 1998-04-20 | 2009-08-26 | ABBOTT GMBH & CO. KG | Amidas sustituidas con heterociclos como inhibidores de la calpaina. |
| CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| CA2531061A1 (en) * | 2003-07-02 | 2005-01-13 | Vertex Pharmaceuticals Incorporated | Pyrimidines useful as modulators of voltage-gated ion channels |
| GB0520581D0 (en) * | 2005-10-10 | 2005-11-16 | Glaxo Group Ltd | Novel compounds |
| GB0520578D0 (en) * | 2005-10-10 | 2005-11-16 | Glaxo Group Ltd | Novel compounds |
| JP2009520700A (ja) * | 2005-12-21 | 2009-05-28 | ペインセプター ファーマ コーポレーション | 依存性イオンチャネルを調節するための組成物および方法 |
| EA015952B1 (ru) * | 2007-05-03 | 2011-12-30 | Пфайзер Лимитед | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов |
| WO2008147864A2 (en) * | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| TW201024282A (en) * | 2008-11-20 | 2010-07-01 | Orion Corp | New pharmaceutical compounds |
-
2011
- 2011-01-12 TW TW100101047A patent/TW201139406A/zh unknown
- 2011-01-13 SG SG2012050068A patent/SG182400A1/en unknown
- 2011-01-13 MA MA35122A patent/MA33987B1/fr unknown
- 2011-01-13 EA EA201290644A patent/EA201290644A1/ru unknown
- 2011-01-13 US US13/522,183 patent/US20130023541A1/en not_active Abandoned
- 2011-01-13 CA CA2787025A patent/CA2787025A1/en not_active Abandoned
- 2011-01-13 BR BR112012017266A patent/BR112012017266A2/pt not_active IP Right Cessation
- 2011-01-13 PE PE2012000982A patent/PE20121518A1/es not_active Application Discontinuation
- 2011-01-13 EP EP11733370.8A patent/EP2523665A4/en not_active Withdrawn
- 2011-01-13 WO PCT/US2011/021114 patent/WO2011088201A1/en not_active Ceased
- 2011-01-13 MX MX2012008285A patent/MX2012008285A/es not_active Application Discontinuation
- 2011-01-13 CN CN2011800141112A patent/CN102802627A/zh active Pending
- 2011-01-13 PH PH1/2012/501421A patent/PH12012501421A1/en unknown
- 2011-01-13 AU AU2011205302A patent/AU2011205302B2/en not_active Ceased
- 2011-01-13 JP JP2012549074A patent/JP2013517283A/ja active Pending
- 2011-01-13 NZ NZ601126A patent/NZ601126A/en not_active IP Right Cessation
- 2011-01-13 KR KR1020127021186A patent/KR20120124064A/ko not_active Withdrawn
- 2011-01-14 AR ARP110100127A patent/AR079906A1/es unknown
- 2011-01-14 UY UY33186A patent/UY33186A/es not_active Application Discontinuation
-
2012
- 2012-07-09 IL IL220836A patent/IL220836A0/en unknown
- 2012-07-10 ZA ZA2012/05126A patent/ZA201205126B/en unknown
- 2012-07-13 CO CO12118387A patent/CO6592051A2/es active IP Right Grant
- 2012-07-13 CL CL2012001971A patent/CL2012001971A1/es unknown
- 2012-07-31 CR CR20120402A patent/CR20120402A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY33186A (enExample) | 2011-07-29 |
| EP2523665A1 (en) | 2012-11-21 |
| ZA201205126B (en) | 2013-03-27 |
| CL2012001971A1 (es) | 2013-01-25 |
| IL220836A0 (en) | 2012-08-30 |
| MA33987B1 (fr) | 2013-02-01 |
| CR20120402A (es) | 2012-09-03 |
| WO2011088201A1 (en) | 2011-07-21 |
| AU2011205302B2 (en) | 2014-10-09 |
| CA2787025A1 (en) | 2011-07-21 |
| CN102802627A (zh) | 2012-11-28 |
| MX2012008285A (es) | 2012-08-03 |
| CO6592051A2 (es) | 2013-01-02 |
| KR20120124064A (ko) | 2012-11-12 |
| EP2523665A4 (en) | 2013-07-03 |
| EA201290644A1 (ru) | 2012-12-28 |
| SG182400A1 (en) | 2012-08-30 |
| TW201139406A (en) | 2011-11-16 |
| BR112012017266A2 (pt) | 2016-04-19 |
| AR079906A1 (es) | 2012-02-29 |
| PH12012501421A1 (en) | 2017-08-09 |
| JP2013517283A (ja) | 2013-05-16 |
| PE20121518A1 (es) | 2012-12-12 |
| US20130023541A1 (en) | 2013-01-24 |
| AU2011205302A1 (en) | 2012-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ602435A (en) | Pyridine and pyrazine derivative for the treatment of cf | |
| MX2010004688A (es) | Usos terapeuticos de compuestos que tienen actividad combinada de sert, 5- ht3 y 5-ht1a. | |
| EA201100423A1 (ru) | Новые бензамиды, их получение и их применение в качестве лекарственных средств | |
| ME02648B (me) | Jedinjenje pirazin karboksamida | |
| CY1116994T1 (el) | 3,5-διαμινο-6-χλωρο-ν-(ν-(4-(4-(2-(εξυλ (2,3,4,5,6-πενταϋδροξυεξυλ) amino) αιθοξυ) φαινυλ) βουτυλ) καρβαμιμιδοϋλ) πυραζινο-2-καρβοξαμιδιο | |
| NZ602795A (en) | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | |
| NZ566788A (en) | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation | |
| NZ592685A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| JP2012520342A5 (enExample) | ||
| MX2010009922A (es) | Activadores de piridazinona glucocinasa. | |
| EA200971086A1 (ru) | Фармацевтические композиции и способ лечения шизофрении | |
| NO20061254L (no) | Farmasoytiske blandinger | |
| NZ604035A (en) | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | |
| TNSN06409A1 (en) | Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof | |
| NZ601483A (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| AR062104A1 (es) | Derivados de quinuclidina como antagonistas de m3 | |
| JP2015516420A5 (enExample) | ||
| MX2009009238A (es) | Nuevos inhibidores de fosfodiesterasa. | |
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| NZ591914A (en) | Naphthylacetic acids | |
| CA2730471A1 (en) | Piperazine derivatives used as cav2.2 calcium channel modulators | |
| NZ710574A (en) | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors | |
| EP2773352A2 (en) | 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists | |
| AR087053A1 (es) | Uso de un compuesto piperazin-piridinico para la fabricacion de una composicion farmaceutica util para el tratamiento de la tos post-viral, la tos viral o la tos aguda viral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |